The company

company's officeVaiomer is a biotech company and contract research organization (CRO) expert in tissue and blood microbiota.

The company was created in 2011 on the pioneering work of its founders, Rémy Burcelin (Inserm) and Jacques Amar (CHU Toulouse) that unraveled the causal role exerted by tissue and blood microbiome in the initiation of an inflammatory cascade leading to cardiometabolic disorders.

The vocation of the company is to contribute to the discovery of innovative tools, biomarkers and therapeutic targets related to tissue microbiome. This new concept helps to establish early prognosis and therapies of numerous diseases such as cardiometabolic diseases (obesity, diabetes, NASH, NAFLD, liver fibrosis, cirrhosis, cardiac failure, etc.), neurodegenerative disorders (Alzheimer, Parkinson, etc.) or infectious diseases (AIDS, septicemia, etc.).

To achieve this goal, Vaiomer has set up state-of-the-art technology in molecular biology, 16S metagenomics, transcriptomics and computational biology to identify bacterial community profiles and host genes that act as key regulators of disease cascades.